HCA Healthcare price target raised to $114 from $97 at Argus.
Argus analyst Jasper Hellweg raised his price target on HCA Healthcare to $114 and kept his Buy rating after Q4 earnings, pointing to the company's strong guidance, positive impact of U.S. tax changes, and expanding business. The analyst also initiates a FY19 EPS view of $9.26, which implies a 8.4% increase from his expected FY18 forecast in addition to his modeled 11% rise in FY19 revenue. Hellweg adds that the company has been able to respond to greater competition in the commercial market and a less favorable payer mix with acquisitions and the strategic use of big data.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 12, 2018|
|Previous Article:||Catalyst Pharmaceuticals announces plans to resubmit NDA for Firdapse.|
|Next Article:||E2open submits proposal to acquire Amber Road for $10.50 per share in cash.|